53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details
臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
Showing 1 to 10 of 305 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05673993 (ClinicalTrials.gov) | April 2023 | 29/12/2022 | A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren' ... | A Phase ?, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Subcutaneous Telitacicept in Subjects With Active Primary Sjogren's Syndrome A Phase ?, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety o ... | Primary Sjogren's Syndrome | Biological: Telitacicept 80 mg;Biological: Telitacicept 160 mg;Drug: Placebo | RemeGen Co., Ltd. | NULL | Not yet recruiting | 18 Years | 70 Years | All | 375 | Phase 3 | China |
2 | NCT05700422 (ClinicalTrials.gov) | February 2023 | 14/1/2023 | Nasal Spray Study in Sjogren's Dry Eye Disease | A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease in Subjects With Sjogren's Syndrome A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (Varenicline Solution) N ... | Sjogren's Syndrome;Dry Eye | Drug: Varenicline Nasal Spray | University of Pennsylvania | Oyster Point Pharma, Inc. | Not yet recruiting | 18 Years | N/A | All | 40 | Phase 4 | NULL |
3 | EUCTR2022-001484-27-NL (EUCTR) | 24/01/2023 | 29/10/2022 | Basta 2 | B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis TissuesAnalysis 2 - Basta 2 B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissue ... | Systemic Sclerosis Sjögren's SyndromeCutaneous Lupus Erythematodus;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Systemic Sclerosis Sjögren's SyndromeCutaneous Lupus Erythematodus;Therapeutic area: Diseases [C] - ... | Product Name: [89Zr]Zr-Df-crefmirlimab berdoxam Product Code: IND 127861 INN or Proposed INN: [89Zr]Zr-Df-crefmirlimab berdoxam Other descriptive name: Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89 Product Name: [89Zr]Zr-Df-crefmirlimab berdoxam Product Code: IND 127861 INN or Proposed INN: [89Zr]Zr ... | radboudumc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Netherlands | ||
4 | NCT05644795 (ClinicalTrials.gov) | January 1, 2023 | 9/11/2022 | Wheat-free Diet in the Treatment of Sjogren's Syndrome | Efficacy of a Wheat-free Diet in Autoimmune Diseases: a Pilot Therapeutic Study in Sjogren's Disease Efficacy of a Wheat-free Diet in Autoimmune Diseases: a Pilot Therapeutic Study in Sjogren's Disease ... | Sjogren's Syndrome;Non-celiac Gluten Sensitivity | Dietary Supplement: Wheat/milk free diet (W/MFD) group;Dietary Supplement: Rice/turkey free diet (R/TFD) group Dietary Supplement: Wheat/milk free diet (W/MFD) group;Dietary Supplement: Rice/turkey free diet (R/ ... | University of Palermo | Aurelio Seidita | Not yet recruiting | 18 Years | 65 Years | All | 30 | N/A | Italy |
5 | EUCTR2021-005911-30-NL (EUCTR) | 27/12/2022 | 24/10/2022 | A Study of the safety and effectiveness of Efgartigimod in Patients with Primary Sjögren’s Syndrome (pSS) A Study of the safety and effectiveness of Efgartigimod in Patients with Primary Sjögren’s Syndrome( ... | A Phase 2, Randomized, Placebo-controlled, Parallel Group, Double-blind, Proof-of-concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sjögren’s Syndrome A Phase 2, Randomized, Placebo-controlled, Parallel Group, Double-blind, Proof-of-concept Study to E ... | Primary Sjögren’s Syndrome MedDRA version: 21.0;Level: LLT;Classification code 10042846;Term: Syndrome Sjogren's;System Organ Class: 100000004859;Therapeutic area: Body processes [G] - Immune system processes [G12] Primary Sjögren’s Syndrome MedDRA version: 21.0;Level: LLT;Classification code 10042846;Term: Syndro ... | Product Name: efgartigimod Product Code: ARGX-113 INN or Proposed INN: Efgartigimod alfa | argenx BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Czechia;Hungary;Belgium;Spain;Poland;Germany;Netherlands | ||
6 | EUCTR2019-002470-32-NL (EUCTR) | 12/12/2022 | 23/07/2021 | NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients NEw Clinical End-points in patients with primary Sjögren’s Syndrome(pSS): an Interventional Trial ba ... | NEw Clinical End-points in patients with primary Sjögren’s Syndrome (pSS): an Interventional Trial based on stratifYing patients - NECESSITY NEw Clinical End-points in patients with primary Sjögren’s Syndrome(pSS): an Interventional Trial ba ... | Primary Sjögren’s syndrome (pSS) MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Body processes [G] - Immune system processes [G12] Primary Sjögren’s syndrome(pSS) MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sj ... | Trade Name: PLAQUENIL Product Name: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine Other descriptive name: HYDROXYCHLOROQUINE SULFATE Trade Name: Mycophenolate mofetil TEVA Product Name: mycophenolate mofetil INN or Proposed INN: Mycophenolate mofetil Other descriptive name: MYCOPHENOLATE MOFETIL Trade Name: Arava Product Name: Leflunomide INN or Proposed INN: LEFLUNOMIDE Trade Name: PLAQUENIL Product Name: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine Other de ... | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 2 | Netherlands;Italy | ||
7 | NCT05605665 (ClinicalTrials.gov) | November 5, 2022 | 29/10/2022 | Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome | Therapeutic Effect of Low Dose IL-2 Combined With Rapamycin in on sjögren's Syndrome | Sjögren's Syndrome | Drug: low-dose interleukin-2;Drug: rapamycin | Peking University People's Hospital | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | China |
8 | NCT05383677 (ClinicalTrials.gov) | October 1, 2022 | 29/3/2022 | Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome | ANIfrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome - Efficacy and Safety Assessment in a Randomized, Double-blind, Placebo-controlled Phase-IIa Proof-of-concept Trial (ANISE-II) ANIfrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome- Efficacy and Safety ... | Sjogren's Syndrome | Drug: Anifrolumab;Drug: Placebo | University Medical Center Groningen | AstraZeneca | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Netherlands |
9 | JPRN-jRCT1031220298 | 27/08/2022 | 27/08/2022 | Mucosta trial | A double-blinded, randomised, clinical trial about the effect of rebamipide ophthalmic suspension in dry eye with the Sjogren syndrome patients. - Mucosta trial A double-blinded, randomised, clinical trial about the effect of rebamipide ophthalmic suspension in ... | Patients with dry eye complicated by Sjogren's syndrome | Each study drug will be administered for a period of 12 weeks from the date of initiation of administration. Mucosta group: Mucosta ophthalmic suspension is administered 4 times a day and observed at 0, 4 and 12 weeks. Hyalein group: Hyalein ophthalmic suspension is administered 6 times a day and observed at 0, 4, and 12 weeks. Each study drug will be administered for a period of 12 weeks from the date of initiation of adminis ... | Shimizu Daisuke | NULL | Recruiting | >= 18age old | Not applicable | Both | 40 | Phase 4 | Japan |
10 | NCT05349214 (ClinicalTrials.gov) | August 4, 2022 | 8/4/2022 | Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren' ... | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Effica ... | Sjogren Syndrome | Biological: VAY736;Other: Placebo | Novartis Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 489 | Phase 3 | United States;Argentina;Australia;Brazil;Bulgaria;Canada;China;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Lebanon;Mexico;Poland;Romania;Slovakia;Spain;Sweden;Taiwan;United Kingdom United States;Argentina;Australia;Brazil;Bulgaria;Canada;China;France;Germany;Greece;Hungary;India;I ... |